All treatments
InjectionWeight LossIn stock

Semaglutide injection

A once-weekly GLP-1 receptor agonist that helps patients achieve clinically significant, sustained weight loss — delivered to your clinic with the infrastructure to scale it.

Launch this programSee the stack
Semaglutide injection
Dose
Once weekly
Avg. loss · 68 wks
−14.9%
Format
Weekly subcutaneous injection
Source
503A/503B compounding pharmacies
Rx required
Yes — licensed provider review
Ships in
2–3 business days
About the medication

A proven GLP-1 therapy, compounded for your program

Semaglutide mimics the GLP-1 hormone to slow gastric emptying, reduce appetite signals, and improve glycemic control. In the pivotal STEP 1 trial, adults with obesity lost an average of ~15% of body weight over 68 weeks — multiples of what diet and exercise alone typically achieve.

  • Reduces hunger and cravings by acting on appetite centers in the brain
  • Slows gastric emptying, improving satiety between meals
  • Supports glycemic control alongside weight loss
  • Delivered subcutaneously once per week — any day, any time
Mechanism
GLP-1 receptor agonist — appetite & satiety pathway
Delivery
Subcutaneous once-weekly injection (abdomen, thigh, arm)
Onset
Appetite changes in days; weight loss builds over 12–68 weeks
Oversight
Every order routed through a licensed provider review
Expected results

Clinically meaningful weight loss, sustained

Based on the STEP 1 trial (68 weeks, 2.4 mg weekly dose). Real-world outcomes depend on titration adherence, lifestyle changes, and individual response — your providers see the same per-patient data in the Turbopills admin console.

14.9%
Avg. total body weight loss
at 68 weeks, 2.4 mg dose
86%
Patients losing ≥5% weight
of completers in pivotal trial
50%
Patients losing ≥15% weight
of completers in pivotal trial
Mean change in body weight
% change from baseline · weeks 0–68
Semaglutide 2.4 mgPlacebo
At week 68
−14.9%
Semaglutide 2.4 mg
At week 68
−2.4%
Placebo
Net difference
−12.5 pts
vs. placebo

Illustrative — based on published STEP 1 trial outcomes. Not a clinical guarantee. Compounded semaglutide formulations may vary and are prescribed off-label at provider discretion.

Dosing protocol

Standard titration schedule

Patients step up gradually to minimize GI side effects. Your providers can override any step and the platform ships the matching vial automatically.

  1. 1
    Weeks 1–4
    0.25 mg
    Initiation — GI side-effect tolerance
  2. 2
    Weeks 5–8
    0.5 mg
    First up-titration
  3. 3
    Weeks 9–12
    1.0 mg
    Therapeutic ramp
  4. 4
    Weeks 13–16
    1.7 mg
    Pre-maintenance
  5. 5
    Week 17+
    2.4 mg
    Maintenance dose
The Turbopills stack for this program

Everything you need to run a semaglutide program

Pick the pieces you want. Use your own brand, your own providers, your own price — powered by a single, compliant backend.

Product website & ad landing pages
Turbopills AI Studio — ad images & videos
Beta
Dynamic intake forms
Billing & subscriptions
Provider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Patient communications
Experiments & A/B tests
Beta
Ready to launch

Ship a semaglutide program in weeks — not quarters.

The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.

Talk to our teamBrowse treatments

Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.

Related

Other weight-loss treatments